P050 Centrally-determined standardization of flow cytometry methods reduces inter-laboratory variation in a prospective multicenter study
Westera L.1, van Viegen T.2, Jeyarajah J.3, Azad A.4, Bilsborough J.5, van den Brink G.1, Danese S.6, D'Haens G.2,7, Eckmann L.8, Faubion W.9, Korf H.10, McGovern D.5, Panes J.11, Salas A.11, Sandborn W.8,12, Silverberg M.4, Smith M.4, Vermeire S.10, Vetrano S.6, Shackelton L.3, Stitt L.3, Jairath V.3,13, Levesque B.8,12, Spencer D.3, Feagan B.3,13, Vande Casteele N.*8,12
1Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands 2Robarts Clinical Trials, Inc., Amsterdam, Netherlands 3Robarts Clinical Trials, Inc., London, Canada 4Mount Sinai Hospital, Toronto, Canada 5F. Widjaja Foundation Inflammatory Bowel and Immunobiology Institute, Los Angeles, United States 6Humanitas University, Milan, Italy 7Academic Medical Center, Amsterdam, Canada 8University of California, San Diego, United States 9Mayo Clinic, Rochester, United States 10University of Leuven, Leuven, Belgium 11Hospital Clínic Barcelona, Barcelona, Spain 12Robarts Clinical Trials, Inc., San Diego, United States 13University of Western Ontario, London, Canada
Flow cytometry (FC) of mucosal biopsy and peripheral blood samples from patients with inflammatory bowel disease aids in characterization of cellular and molecular factors involved in the pathologic immune response in these diseases. This technique has potential to facilitate early drug development and elucidate mechanisms of action of prospective therapies. Lack of standardized methods and variation in FC outcomes across laboratories hamper its use in multicenter clinical trials. We compared the variation in 3 FC strategies among international laboratories.
Peripheral blood mononuclear cells (PBMCs) were isolated from buffy coats from 3 healthy volunteers, cultured in a cocktail +/− phorbol 12-myristate 13-acetate and ionomycin at a central laboratory, and then fixed, frozen, and shipped on dry ice to 7 international laboratories. Permeabilization and staining of PBMCs was performed at each laboratory in triplicate using a common protocol and centrally-provided reagents. Gating was performed according to 3 strategies: local gating with a local strategy, local gating with a central strategy, and central gating. A range of cell populations, with high or low event numbers and in stimulated and unstimulated conditions was chosen for analyses. Mean cell proportion was calculated across triplicates and within donors, conditions and strategies. The coefficient of variation (CV) for each FC parameter was calculated across laboratories. Among-strategy comparisons were made using a two-way ANOVA, adjusting for donor.
Mean inter-laboratory CV ranged from 2.1%–74.1% depending on cell population and gating strategy (5.1%–74.1% for local gating with a local strategy, 10.9%–65.6% for local gating with a central strategy, and 2.1%–20.9% for central gating [Table 1]).
For each FC parameter, mean-inter laboratory CV differed significantly across gating strategies and variability was consistently lower with central gating, which reduced mean inter-laboratory CV by 3%-67%, depending on cell population.
Flow cytometry can be performed by multiple international laboratories with reasonable precision using a common protocol for permeabilization and staining, and centrally-performed gating. Central gating was the only strategy with mean CVs consistently lower than 25%; a proposed standard for pharmacodynamic and exploratory biomarker assays . Our results suggest that gating is a major source of variability in FC.
 O'Hara DM et al, (2011), Recommendations for the validation of flow cytometric testing during drug development: II assays, J Immunol Methods, 120